Weight-loss drugmaker Novo Nordisk invests $1.2 bn in new factory in Denmark
Danish pharmaceutical giant Novo Nordisk, maker of diabetes and weight-loss treatments Ozempic and Wegovy, said Monday it was investing 8.5 billion kroner ($1.2 billion) to build a new factory in Denmark to produce drugs against rare diseases.
20hon MSN
The end of Novo Nordisk’s supply problems could bring new headaches for the rest of the pharmaceutical industry, which now ...
14mon MSN
A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news ...
The maker of weight-loss and diabetes drugs has supercharged the Danish economy — but other businesses complain that’s left ...
Eli Lilly (LLY -1.28%) and Novo Nordisk (NVO 1.03%) have competed for decades. They're both leaders in the areas of insulin ...
Eli Lilly's popular weight-loss drug Zepbound outperformed Danish drugmaker Novo Nordisk's Wegovy in a clinical trial, ...
Wegovy and other GLP-1 medications have become extremely popular over the past few years. Novo Nordisk (which makes both Wegovy and Ozempic) and other drug manufacturers have invested heavily ...
NVO's CagriSema target of up to 25% in long-term weight loss is highly promising vs. 15% through Wegovy and 20% through ...
Eli Lilly & Co. said its weight-loss drug Zepbound outperformed rival Novo Nordisk A/S’s Wegovy in the first ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback